Sugi Predict

Sugi Predict / Compounds / SCHEMBL2663017

SCHEMBL2663017

SCHEMBL2663017

CCCCOc1ccc(NC(=O)N(Cc2ccc(C(=O)NCCC(=O)O)s2)Cc2ccccc2OC(F)(F)F)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 7/20 0.45
▸ EPHX2 P34913 10/20 0.42
▸ GLP1R P43220 2/20 0.40
▸ GIPR P48546 2/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ FFAR4 Q5NUL3 1/20 0.39
▸ S1PR1 P21453 1/20 0.39
▸ S1PR3 Q99500 1/20 0.39
▸ ADCY6 O43306 1/20 0.39
▸ ADCY3 O60266 1/20 0.39
▸ ADCY9 O60503 1/20 0.39
▸ ADCY5 O95622 1/20 0.39
▸ ADCY8 P40145 1/20 0.39
▸ ADCY7 P51828 1/20 0.39
▸ ADCY2 Q08462 1/20 0.39
▸ ADCY1 Q08828 1/20 0.39
▸ ADCY4 Q8NFM4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2663008 0.86 EPHX2 (0.41) GCGREPHX2
SCHEMBL2663138 0.86 GCGR (0.46) GCGREPHX2
SCHEMBL4091737 0.81 GCGR (0.50) GCGRGLP1RGIPRS1PR1S1PR3
SCHEMBL4086435 0.79 GCGR (0.40) GCGREPHX2NPSR1FFAR4S1PR1
SCHEMBL4091860 0.79 GCGR (0.59) GCGRGLP1RGIPRADCY6ADCY3
SCHEMBL4095294 0.71 GCGR (0.51) GCGRGLP1RGIPRADCY6ADCY3
SCHEMBL2663131 0.71 GCGR (0.60) GCGREPHX2GLP1RGIPRADCY6
SCHEMBL4091683 0.71 GCGR (0.61) GCGRGLP1RGIPRADCY6ADCY3
SCHEMBL2662994 0.70 GCGR (0.42) GCGREPHX2GLP1RGIPRADCY6
SCHEMBL2662989 0.70 GCGR (0.74) GCGRGLP1RGIPRADCY6ADCY3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885EPHX2 3463/4885GLP1R 1/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885EPHX2 3463/4885GLP1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.